Guerbet, the global specialist in contrast media and solutions for diagnostic and interventional medical imaging, has announced its presence at the 2018 annual congress of the CIRSE (Cardiovascular & Interventional Radiological Society of Europe), to be held from September 22 to 25, 2018 in Lisbon (Portugal).
Villepinte (France), September 20, 2018 -- Guerbet, the global specialist in contrast media and solutions for diagnostic and interventional medical imaging, has announced its presence at the 2018 annual congress of the CIRSE (Cardiovascular & Interventional Radiological Society of Europe), to be held from September 22 to 25, 2018 in Lisbon (Portugal).
Guerbet will present its innovative solutions for interventional imaging, currently driving its growth, at an exhibition booth and in its Innovation Lab. Events will include two symposia on vascular anomalies embolization and cTACE (conventional transarterial chemoembolization) procedures that will take place on Sunday, September 23 and Monday, September 24 from 1 to 2 p.m.
“Our participation is a further demonstration of our interventional imaging expertise and commitment”said Guerbet Interventional Radiology Commercial VP Thomas Bonnefont. “We are continuing to develop our portfolio with the objective of helping healthcare professionals improve the quality of treatment in image-guided embolization procedures.”
Guerbet will be presenting its portfolio of new solutions, along with Guerbet’s flagship product Lipiodol® Ultra Fluid, in the Guerbet Innovation Lab, enabling interventional radiologists to discover and test them.
Among these new solutions, Vectorio®, which is an innovative mixing and injection system that standardizes conventional transarterial chemoembolization (cTACE). It is a unique kit of medical devices resistant[1] to Lipiodol® Ultra Fluid that contains syringes, a patented stopcock and withdrawing accessories. Vectorio® was CE marked in August 2017. The kit is used for mixing and administering Lipiodol® Ultra Fluid combined with an anti-cancer drug during cTACE procedures in adults suffering from intermediate-stage hepatocellular carcinoma (HCC).
For 10 years, the CIRSE congress has been the most prominent annual event organized for interventional radiology professionals. Its 250 hours of workshops and conferences, involving international experts and more than a hundred exhibitors, have attracted some 6,700 participants in previous years. It is a unique opportunity for professionals to share their knowledge of imaging, minimally invasive interventional procedures and latest research findings.
About Guerbet
Guerbet is a pioneer in the contrast-agent field, with more than 90 years’ experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its three centers in France and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B - mid caps) and generated €807 million in revenue in 2017. For more information about Guerbet, please visit www.guerbet.com.
About Vectorio®
Vectorio® is a medical device of Class Is (CE 0459) intended to be used by healthcare professionals only. Manufacturer: Medex, a Guerbet Group company. Intended use: Lipiodol® Resistant Mixing and Injection System for conventional Trans-Arterial Chemo-Embolization (cTACE). For complete information please refer to Instruction For Use.
About Lipiodol® Ultra-Fluid
Lipiodol® Ultra-Fluid (ethyl esters of iodized fatty acids of poppyseed oil) was initially developed for diagnostic radiology in indications including liver lesion diagnosis, lymphography and hysterosalpingography, and then used in interventional radiology for conventional trans-arterial chemo-embolization (cTACE) procedures of multinodular hepatocellular carcinoma, where Lipiodol® Ultra-Fluid was used as a procedure visualizer (contrast agent), a drug vehicle (drug carrier), and an embolic. The approved indications for Lipiodol® Ultra-Fluid may vary according to countries. For complete information please refer to local Summary of Product Characteristics.
Media Relations
Alize RP
Caroline Carmagnol, Isabelle Sauval-Dupuy, Tatiana Vieira
+33 (0)1 44 54 36 66 / +33 (0)6 31 13 76 20
